AUS
NZ
UK
CA
USA
IND
The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) has launched a comprehensive direct-to-consumer retail and telehealth website now accessible throughout all 50 U.S. states. This innovative platform combines oral supplements, transdermal patches, topical wellness products, and telehealth services into a unified consumer-facing site, backed by a 503A compounding agreement ensuring 100% U.S.-compounded peptide products and LegitScript Healthcare Merchant Certification. The rollout precedes the FDA advisory committee’s scheduled review on July 23, 2026, of several peptide substances including BPC-157.
Key Highlights
- The Precision Peptide Company (CSE: BPC) has launched its direct-to-consumer and telehealth platform nationwide, covering all 50 U.S. states.
- The platform integrates oral supplements, transdermal patches, topical products, and telehealth services into one seamless consumer website at www.precisionpeptidecompany.com.
- All peptide products are 100% compounded domestically under a 503A compounding agreement, supported by LegitScript Healthcare Merchant Certification to ensure compliance and facilitate payment processing.
- The launch aligns with the upcoming FDA advisory committee meeting on July 23, 2026, which will review peptide substances including BPC-157, with BPC’s infrastructure now fully operational ahead of this review.
Launch of Nationwide Direct-to-Consumer Platform Enhances Market Reach
On July 21, 2026, The Precision Peptide Company announced the activation of its direct-to-consumer retail and telehealth website, now live and available across all 50 U.S. states. This platform marks a major expansion in the company’s commercial footprint by providing a single integrated online channel for consumers to explore, purchase, and learn about its growing wellness product portfolio.
The website consolidates multiple product categories and telehealth services into one user-friendly digital platform. This integration simplifies consumer access to peptide-based wellness products while enabling BPC to establish direct relationships with end users. The platform aims to deliver clear product information, streamlined purchasing, and telehealth access, positioning the company to deepen consumer engagement as it scales its U.S. operations.
Broad Product Range Spanning Multiple Wellness Segments
The current product lineup available through the platform includes various formats targeting diverse wellness needs. Oral supplements support daily energy, mental focus, muscle and joint health, gut wellness, relaxation, sleep, and recovery. Topical products promote scalp, follicle, and skin health, while transdermal patches focus on recovery, immunity, and other wellness benefits.
This multi-format approach enables BPC to offer a versatile product range catering to different consumer preferences and use cases. By combining oral, topical, and transdermal delivery methods, the platform broadens accessibility to peptide-enhanced wellness and provides multiple engagement points with the company’s brand and offerings.
Innovative Needle-Free Transdermal Patch Technology
A standout feature of BPC’s portfolio is its transdermal patch technology, positioned as a convenient, needle-free alternative to conventional peptide delivery. These patches apply directly to the skin without needles, mixing, or refrigeration, enhancing ease of use and consumer accessibility.
The company’s transdermal strategy emphasizes stabilization, permeation, and sustained-release to create stable, consumer-ready formats that overcome traditional peptide delivery barriers. This patch format is designed to integrate seamlessly into wellness routines, expanding peptide product adoption across a wider market.
U.S.-Based 503A Compounding Agreement and Manufacturing
The platform launch leverages regulatory and operational frameworks established previously. BPC holds a 503A compounding agreement mandating that all peptide products are fully compounded within the United States. This domestic manufacturing approach ensures compliance with U.S. pharmacy compounding standards and supports the company’s direct-to-consumer business model.
The 503A pathway is central to BPC’s U.S. commercial strategy, guaranteeing regulatory adherence for compounded medications. This infrastructure is now operational and integrated with the telehealth and retail platform, enabling compliant service to customers nationwide.
LegitScript Healthcare Merchant Certification Enhances Compliance and Operations
The platform is supported by LegitScript Healthcare Merchant Certification, independently verifying compliance and consumer safety standards. This certification facilitates payment processing and marketing activities across major platforms, addressing critical operational needs for direct-to-consumer health businesses.
The platform complies with U.S. legal requirements, HIPAA, telehealth regulations, and pharmacy standards, ensuring secure consumer interactions. The combined 503A compounding agreement, LegitScript certification, and telehealth infrastructure create a comprehensive compliance ecosystem supporting nationwide operations.
Strategic Readiness Ahead of FDA Advisory Committee Review
The timing of the platform launch is strategically aligned with the FDA’s upcoming review of peptide substances, including BPC-157, scheduled for July 23, 2026 by the Pharmacy Compounding Advisory Committee (PCAC).
BPC enters this regulatory review with its U.S. compounding agreement, telehealth infrastructure, LegitScript certification, and consumer-facing retail website fully operational. This positions the company to effectively respond to potential regulatory changes while continuing product expansion and consumer outreach. The outcome of the FDA review remains uncertain, but BPC’s infrastructure supports ongoing compliance and growth.
Direct Consumer Engagement and Commercial Growth Strategy
The website launch aims to establish direct consumer relationships, granting BPC enhanced control over product education, branding, and customer experience. This direct-to-consumer model contrasts with traditional wholesale or third-party retail channels, providing insights into consumer preferences and purchasing behavior.
The platform supports key commercial goals including customer acquisition, repeat sales, future subscription models, and product line expansion. BPC plans to leverage the integrated platform—combining product info, online purchasing, and telehealth—to scale customer relationships and drive long-term revenue growth.
Integrated Telehealth Services and Regulatory Compliance
Building on telehealth infrastructure announced in June 2026, the platform integrates telehealth services with direct product sales, offering an end-to-end consumer experience. Customers can access professional guidance, obtain prescriptions or recommendations, and purchase products through a single platform, enhancing trust and engagement.
The platform adheres to HIPAA and telehealth regulations, ensuring secure consumer interactions. This integration reduces barriers to peptide product adoption and supports consumer confidence in wellness offerings.
Market Positioning and Competitive Advantage Amid Regulatory Uncertainty
By launching a nationwide direct-to-consumer platform ahead of the FDA advisory committee meeting on July 23, 2026, BPC positions itself to capture market access during regulatory uncertainty. The company’s operational readiness—including compounding, telehealth, payment certification, and consumer technology—provides a competitive edge if regulations remain favorable to compliant U.S.-based peptide compounders.
The announcement does not disclose current sales, customer metrics, or financial forecasts. Investors will likely monitor updates on consumer adoption, repeat purchases, revenue from the direct-to-consumer channel, and scalability. Success depends on regulatory outcomes, consumer acceptance of transdermal formats, and competition within the peptide wellness sector.
